Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

PRFX - PAINREFORM LTD.

2.93
-0.040   -1.365%

Share volume: 39,730
Last Updated: 03-11-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.03%

PREVIOUS CLOSE
CHG
CHG%
$2.97
-0.04
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
8%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 20%
Performance
5 Days
-4.25%
1 Month
2.45%
3 Months
0.34%
6 Months
253.01%
1 Year
46.50%
2 Year
-43.22%
Key data
Stock price
$2.93
P/E Ratio 
0.00
DAY RANGE
$2.84 - $2.96
EPS 
N/A
52 WEEK RANGE
$0.20 - $16.63
52 WEEK CHANGE
$50.26
MARKET CAP 
1.567 M
YIELD 
N/A
SHARES OUTSTANDING 
7.026 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.14
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$69,131
AVERAGE 30 VOLUME 
$2,177,554
Company detail
CEO: Ilan Hadar
Region: US
Website: painreform.com
Employees: 4
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

PainReform Ltd. engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair.

Recent news